No Data
No Data
Sinopharm Prepares for Extraordinary General Meeting
Hong Kong Shares Rise 0.9%, Tracking Wall's Street Gains -- Market Talk
Sinopharm released its interim results, with shareholders' net profit decreasing by 9.76% year-on-year to 3.7039 million yuan.
Sinopharm (01099) released its performance for the six months ended June 30, 2024, with the group achieving revenue of 0.295 billion yuan (RMB, the same below), a year-on-year decrease of 2.07%; the net profit attributable to owners of the parent company was 3.7039 million yuan, a year-on-year decrease of 9.76%; basic earnings per share were 1.19 yuan. The announcement stated that the decrease in revenue was due to the decline in revenue from the group's medical retail business and medical device distribution business.
Sinopharm Proposes New Auditors for 2024
Sinopharm (01099) released its interim performance. Shareholders' attributable net profit was 3.7039 million yuan, a year-on-year decrease of 9.76%.
Sinopharm (01099) released its performance for the six months ended June 30, 2024, during which the Group achieved revenue...
Sinopharm Group: Board Decided Not to Recommend Payout of Interim Dividend>1099.HK
No Data